These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19302716)

  • 1. Circulating cell death products predict clinical outcome of colorectal cancer patients.
    Koelink PJ; Lamers CB; Hommes DW; Verspaget HW
    BMC Cancer; 2009 Mar; 9():88. PubMed ID: 19302716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C.
    Yilmaz Y; Dolar E; Ulukaya E; Akgoz S; Keskin M; Kiyici M; Yerci O; Oral AY; Gul CB; Gurel S; Nak SG; Gulten M
    Med Sci Monit; 2009 Apr; 15(4):CR189-93. PubMed ID: 19333204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response.
    Scott LC; Evans TR; Cassidy J; Harden S; Paul J; Ullah R; O'Brien V; Brown R
    Br J Cancer; 2009 Aug; 101(3):410-7. PubMed ID: 19603019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer.
    Greystoke A; Dean E; Saunders MP; Cummings J; Hughes A; Ranson M; Dive C; Renehan AG
    Br J Cancer; 2012 Oct; 107(9):1518-24. PubMed ID: 22996610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival.
    Ulukaya E; Yilmaztepe A; Akgoz S; Linder S; Karadag M
    Lung Cancer; 2007 Jun; 56(3):399-404. PubMed ID: 17316892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.
    Kramer G; Schwarz S; Hägg M; Havelka AM; Linder S
    Br J Cancer; 2006 Jun; 94(11):1592-8. PubMed ID: 16685278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
    Cummings J; Ranson M; Lacasse E; Ganganagari JR; St-Jean M; Jayson G; Durkin J; Dive C
    Br J Cancer; 2006 Jul; 95(1):42-8. PubMed ID: 16804528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
    de Haas EC; di Pietro A; Simpson KL; Meijer C; Suurmeijer AJ; Lancashire LJ; Cummings J; de Jong S; de Vries EG; Dive C; Gietema JA
    Neoplasia; 2008 Oct; 10(10):1041-8. PubMed ID: 18813353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Predictive value of Glasgow prognostic score in patients with colorectal cancer undergoing laparoscopic radical resection].
    Cao X; Yu T; Zhao G; Xiao G
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Oct; 19(10):1133-1138. PubMed ID: 27781250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocyte-to-monocyte ratio predicts survival after radiofrequency ablation for colorectal liver metastases.
    Facciorusso A; Del Prete V; Crucinio N; Serviddio G; Vendemiale G; Muscatiello N
    World J Gastroenterol; 2016 Apr; 22(16):4211-8. PubMed ID: 27122671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer.
    Böckelman C; Beilmann-Lehtonen I; Kaprio T; Koskensalo S; Tervahartiala T; Mustonen H; Stenman UH; Sorsa T; Haglund C
    BMC Cancer; 2018 Jun; 18(1):679. PubMed ID: 29929486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer.
    Kwon KA; Kim SH; Oh SY; Lee S; Han JY; Kim KH; Goh RY; Choi HJ; Park KJ; Roh MS; Kim HJ; Kwon HC; Lee JH
    BMC Cancer; 2010 May; 10():203. PubMed ID: 20465852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caspase-Cleaved Cytokeratin 18 Fragment M30 as a Potential Biomarker of Macrovascular Invasion in Hepatocellular Carcinoma.
    Elalfy H; Besheer T; Arafa MM; El-Hussiny MA; El Latif MA; Alsayed SAM
    J Gastrointest Cancer; 2018 Sep; 49(3):260-267. PubMed ID: 28361205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cytokeratin 18 as a biomarker for gastric cancer.
    Oyama K; Fushida S; Kinoshita J; Okamoto K; Makino I; Nakamura K; Hayashi H; Inokuchi M; Nakagawara H; Tajima H; Fujita H; Takamura H; Ninomiya I; Kitagawa H; Fujimura T; Ohta T
    Clin Exp Med; 2013 Nov; 13(4):289-95. PubMed ID: 22825587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients.
    Ausch C; Buxhofer-Ausch V; Olszewski U; Hinterberger W; Ogris E; Schiessel R; Hamilton G
    Eur J Surg Oncol; 2009 Nov; 35(11):1164-8. PubMed ID: 19254831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
    Linder S; Olofsson MH; Herrmann R; Ulukaya E
    Expert Rev Mol Diagn; 2010 Apr; 10(3):353-9. PubMed ID: 20370591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total and caspase-cleaved cytokeratin 18 in chronic cholecystitis: a prospective study.
    Simopoulos C; Tsaroucha AK; Asimakopoulos B; Giatromanolaki A; Gavriilidis P; Polychronidis A; Karayiannakis A
    BMC Gastroenterol; 2008 May; 8():14. PubMed ID: 18460214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.
    Dive C; Smith RA; Garner E; Ward T; George-Smith SS; Campbell F; Greenhalf W; Ghaneh P; Neoptolemos JP
    Br J Cancer; 2010 Feb; 102(3):577-82. PubMed ID: 20051949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.